ArticleBMC infectious diseases2026
Whole-genome sequencing suggests recent transmission of rifampicin-resistant tuberculosis in Botswana.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
backgroundTuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), continues to be a global health challenge. Transmission of drug-resistant TB (DR-TB) poses a significant threat to effective TB prevention and care strategies. This study's aim was to investigate transmission patterns of DR-TB strains, identify factors associated with the spread and reconstruct their transmission dynamics over the study period in Botswana.
methodsWe analysed whole-genome sequencing data for 195 rifampicin-resistant Mtb isolates, which were isolated between 2016 and 2023. Potential recent transmission clusters were identified using thresholds of 0 and 5 single-nucleotide polymorphisms (SNPs). The temporal signal for the predominant sublineages was assessed in TemPest, and BEAST was used to infer the evolution of Mtb strains over time. All statistical analyses were performed using STATA version 18.
resultsOf the 195 RR-TB isolates, 116 (60%) belonged to lineage 4. By inferring close genomic relatedness between isolates (0 SNPs and ≤ 5 SNPs difference), there was evidence of transmission. Phylogenetic analyses and SNP differences showed evidence of potential transmission events within and across different health districts. At a 0-SNP cut-off to define genomic clusters, being female (OR: 1.68, 95% CI: 1.04-2.7, p = 0.04) and being infected with a lineage 4 strain (OR: 2.80, 95% CI: 1.19-6.80, p = 0.02) were associated with clustering. Treatment history (OR: 1.41, 95% CI: 0.74-2.69, p = 0.30), smear result (OR: 1.11, 95% CI: 0.64-1.95, p = 0.71) and HIV status (OR: 0.58, 95% CI: 0.71-1.87, p = 0.58) were not associated with clustering.
conclusionsOur study offers insights into the transmission of rifampicin-resistant Mtb in Botswana. The findings indicate that targeted interventions in health districts showing evidence of transmission could help stop the spread of drug-resistant Mtb strains.' CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.